Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00004381 · ClinicalTrials.gov registry record · Phase 2

Phase II Randomized Study of Tin Mesoporphyrin for Neonatal Hyperbilirubinemia

A Phase 2 study, sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).

Completed
Registry status
Phase 2
Development phase

NCT00004381 is a Phase 2 study that has completed, run by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00004381, a Phase 2 study, has completed, sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).

COMPLETED
Registry status
Phase 2
Development phase

Study Summary

OBJECTIVES: I. Compare the efficacy of preventive vs. therapeutic tin mesoporphyrin in direct Coombs' test-positive ABO hemolytic disease of the newborn and glucose-6-phosphate dehydrogenase deficiency in infants living in Greece. II. Assess the safety of tin mesoporphyrin in high-risk newborns.

Interventions

  • DRUG tin mesoporphyrin

Trial Details

FieldValue
Start Date 1999-12
Phase Phase 2

What the Registry Record Tells You About NCT00004381

The ClinicalTrials.gov registry entry for NCT00004381 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), which has 305 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which tin mesoporphyrin is the first listed.

NCT00004381 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00004381 about?

NCT00004381 is a clinical study titled "Phase II Randomized Study of Tin Mesoporphyrin for Neonatal Hyperbilirubinemia". OBJECTIVES: I. Compare the efficacy of preventive vs. therapeutic tin mesoporphyrin in direct Coombs' test-positive ABO hemolytic disease of the newborn and glucose-6-phosphate dehydrogenase deficiency in infants living in Greece. II. Assess the safety of tin mesoporphyrin in high-risk newborns.

What is the current status of trial NCT00004381?

This trial is currently completed. It is a Phase 2 study. The study started on 1999-12.

What interventions are being tested in trial NCT00004381?

The interventions under investigation include: tin mesoporphyrin (DRUG).

Who is sponsoring clinical trial NCT00004381?

This trial is sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), which has 305 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.